We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

181 hedge funds and large institutions have $1.73B invested in Nektar Therapeutics in 2015 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 23

38% more call options, than puts

Call options by funds: $6.54M | Put options by funds: $4.74M

24% more capital invested

Capital invested by funds: $1.39B → $1.73B (+$338M)

18% more funds holding

Funds holding: 153 → 181 (+28)

18% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 45

Holders
181
Holders Change
+28
Holders Change %
+18.3%
% of All Funds
4.87%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
51
Increased
53
Reduced
45
Closed
23
Calls
$6.54M
Puts
$4.74M
Net Calls
+$1.8M
Net Calls Change
-$2.58M

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$50.7M
2
First Trust Advisors
First Trust Advisors
Illinois
+$39.3M
3
CCM
Camber Capital Management
Massachusetts
+$17.2M
4
GAM
Gotham Asset Management
New York
+$15.6M
5
BA
BlackRock Advisors
Delaware
+$14.1M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$41.1M
2
BIT
BlackRock Institutional Trust
California
-$13.2M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$11.4M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$7.72M
5
DFO
Duquesne Family Office
New York
-$7.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
BJCM
26
Blue Jay Capital Management
California
$11.6M +$10.6M +61,667 New
Geode Capital Management
27
Geode Capital Management
Massachusetts
$10.5M +$317K +1,844 +3%
GC
28
Guggenheim Capital
Illinois
$9.42M +$3.84M +22,335 +80%
CS
29
Credit Suisse
Switzerland
$8.28M +$2.35M +13,672 +45%
TCIM
30
TIAA CREF Investment Management
New York
$7.89M -$1.07M -6,206 -13%
Ameriprise
31
Ameriprise
Minnesota
$7.74M +$6.48M +37,665 +1,047%
Artisan Partners
32
Artisan Partners
Wisconsin
$7.67M +$64K +372 +0.9%
HCM
33
Harvey Capital Management
Florida
$7.37M +$3.51M +20,393 +97%
EAM
34
Eagle Asset Management
Florida
$7.29M -$43.2K -251 -0.6%
BIM
35
BlackRock Investment Management
Delaware
$7.24M +$2.34M +13,626 +55%
Charles Schwab
36
Charles Schwab
California
$6.93M +$2.23M +12,973 +54%
Morgan Stanley
37
Morgan Stanley
New York
$6.67M -$264K -1,535 -4%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$6.58M -$2.56M -14,867 -30%
AllianceBernstein
39
AllianceBernstein
Tennessee
$6.36M – – –
RHJA
40
Rice Hall James & Associates
California
$6.01M -$544K -3,161 -9%
AGA
41
Altrinsic Global Advisors
Connecticut
$5.75M – – –
American Century Companies
42
American Century Companies
Missouri
$5.75M +$5.27M +30,613 New
Goldman Sachs
43
Goldman Sachs
New York
$5.6M -$1.36M -7,929 -21%
CS
44
Candriam SCA
Luxembourg
$5.5M +$1.38M +8,000 +38%
CAM
45
Cormorant Asset Management
Massachusetts
$4.97M – – –
Millennium Management
46
Millennium Management
New York
$4.94M -$5.2M -30,226 -53%
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$4.62M -$56.3K -327 -1%
OPPM
48
Opus Point Partners Management
New York
$4.6M +$371K +2,154 +10%
ACH
49
ArrowMark Colorado Holdings
Colorado
$4.57M – – –
CCMU
50
Cheyne Capital Management (UK)
United Kingdom
$4.3M -$2.82M -16,373 -42%
1
2
3 4 5

NKTR Hedge Fund Activity: Q2 2015 in Review

181 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2015, worth a combined $1.73B — up 24% from $1.39B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new NKTR positions and 23 closed out — a net gain of 28 holders — while 53 added to existing stakes and 45 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $50.7M. The largest seller was JP Morgan Chase, cutting an estimated $41.1M.

  • 181 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2015, up from 153 in Q1 2015.
  • Funds reported $1.73B of Nektar Therapeutics stock for Q2 2015, up 24% quarter-over-quarter.
  • 51 funds opened new Nektar Therapeutics positions in Q2 2015 and 23 closed out, a net change of +28 holders.
  • The largest Nektar Therapeutics buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $50.7M added.
  • The largest Nektar Therapeutics seller in Q2 2015 was JP Morgan Chase, an estimated $41.1M sold.

Based on aggregated 13F filings for Q2 2015.